Secukinumab gets FDA nod for nr-axSpA
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
DGAT2 a potential therapeutic target for fatty liver?
Antisense inhibition of DGAT2* – one of two vital enzymes in triglyceride synthesis – may be a favourable strategy for reversing nonalcoholic fatty liver disease (NAFLD), suggesting that targeting this pathway may mitigate NAFLD progression to its more severe form, nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Color 1
Color 2